BioCentury | Jun 22, 2018
Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

...Nan Fung Technology's Pivotal Beta and Morningside Ventures, respectively. Also participating were funds associated with Atlantis...
BioCentury | Jun 18, 2018
Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

...note rounds led by Nan Fung Technology's Pivotal Beta. Also participating were funds associated with Atlantis...
BioCentury | Mar 22, 2018
Translation in Brief

Mining marine metabolites

...Co. (NYSE:BMY) is tapping Sirenas LLC’s AI platform Atlantis to discover microbiome metabolites for immuno-oncology. Atlantis...
...to,” said CEO Jake Beverage, adding that the “chemistry is much more evolved.” Esquenazi said Atlantis...
BioCentury | Mar 1, 2018
Targets & Mechanisms

Checking out the microbiome

...Diego, Calif. 2011 $1.7 (A) Bristol-Myers Squibb Co. (NYSE:BMY) Discovering drugs against undisclosed targets using Atlantis...
BioCentury | Feb 16, 2018
Company News

Sirenas, BMS partner on drug discovery for "challenging" targets

...Co. (NYSE:BMY) partnered to use Sirenas' ATLANTIS drug discovery platform against several undisclosed "challenging" targets. ATLANTIS...
BioCentury | Oct 24, 2016
Company News

California Institute for Biomedical Research, Sirenas LLC deal

...neglected diseases. Sirenas will provide the institute access to the company’s marine-derived chemical diversity and Atlantis...
BioCentury | Aug 8, 2016
Clinical News

Lurbinectedin: Phase III started

...PharmaMar began the open-label, international Phase III ATLANTIS trial to compare PM1183 plus doxorubicin vs. topotecan...
BioCentury | Apr 30, 2012
Company News

Valeant Pharmaceuticals, Atlantis S.A. de C.V. deal

...Valeant will acquire assets from branded generic company Atlantis, including gastrointestinal, analgesics and anti-inflammatory products for...
...close this quarter. Details were not disclosed. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec Atlantis S.A. de C.V....
BioCentury | Mar 17, 2003
Company News

Atlantis BioActives Corp., Bioxel deal

...provide large-scale production of intermediate taxanes extracted from BIP’s yew biomass for cGMP paclitaxel production. Atlantis...
BioCentury | Jul 27, 1998
Clinical News

Activase alteplase tPA: Phase III data; marketed

...GNE terminated its U.S. Phase III ATLANTIS trial (Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic...
Items per page:
1 - 10 of 12
BioCentury | Jun 22, 2018
Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

...Nan Fung Technology's Pivotal Beta and Morningside Ventures, respectively. Also participating were funds associated with Atlantis...
BioCentury | Jun 18, 2018
Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

...note rounds led by Nan Fung Technology's Pivotal Beta. Also participating were funds associated with Atlantis...
BioCentury | Mar 22, 2018
Translation in Brief

Mining marine metabolites

...Co. (NYSE:BMY) is tapping Sirenas LLC’s AI platform Atlantis to discover microbiome metabolites for immuno-oncology. Atlantis...
...to,” said CEO Jake Beverage, adding that the “chemistry is much more evolved.” Esquenazi said Atlantis...
BioCentury | Mar 1, 2018
Targets & Mechanisms

Checking out the microbiome

...Diego, Calif. 2011 $1.7 (A) Bristol-Myers Squibb Co. (NYSE:BMY) Discovering drugs against undisclosed targets using Atlantis...
BioCentury | Feb 16, 2018
Company News

Sirenas, BMS partner on drug discovery for "challenging" targets

...Co. (NYSE:BMY) partnered to use Sirenas' ATLANTIS drug discovery platform against several undisclosed "challenging" targets. ATLANTIS...
BioCentury | Oct 24, 2016
Company News

California Institute for Biomedical Research, Sirenas LLC deal

...neglected diseases. Sirenas will provide the institute access to the company’s marine-derived chemical diversity and Atlantis...
BioCentury | Aug 8, 2016
Clinical News

Lurbinectedin: Phase III started

...PharmaMar began the open-label, international Phase III ATLANTIS trial to compare PM1183 plus doxorubicin vs. topotecan...
BioCentury | Apr 30, 2012
Company News

Valeant Pharmaceuticals, Atlantis S.A. de C.V. deal

...Valeant will acquire assets from branded generic company Atlantis, including gastrointestinal, analgesics and anti-inflammatory products for...
...close this quarter. Details were not disclosed. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec Atlantis S.A. de C.V....
BioCentury | Mar 17, 2003
Company News

Atlantis BioActives Corp., Bioxel deal

...provide large-scale production of intermediate taxanes extracted from BIP’s yew biomass for cGMP paclitaxel production. Atlantis...
BioCentury | Jul 27, 1998
Clinical News

Activase alteplase tPA: Phase III data; marketed

...GNE terminated its U.S. Phase III ATLANTIS trial (Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic...
Items per page:
1 - 10 of 12